Phase 3
Active (not recruiting)

Obinutuzumab (Gazyva)

Timeline
Study Dates
Start Date
January 2023
Est. Completion
December 2026
Enrollment Target
500 participants
Status
Active (not recruiting)
Study Design
Primary Endpoint
Proportion of patients achieving a clinically relevant improvement (≥4 point increase) in SLE Responder Index-4 (SRI-4) at 52 weeks
⚠ No ClinicalTrials.gov registry ID found for this program. This trial was announced but no registered study has been identified. CelluTarget flags this distinction rather than treating announced and registered trials as equivalent.
Related Treatment
Treatment Being Studied
Obinutuzumab (Gazyva)